Comprehensive Stock Comparison
Compare Syndax Pharmaceuticals, Inc. (SNDX) vs Exelixis, Inc. (EXEL) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth | SNDX | 6.0% revenue growth vs EXEL's 7.0% |
| Quality / Margins | EXEL | 29.6% net margin vs SNDX's -279.3% |
| Stability / Safety | EXEL | Beta 0.63 vs SNDX's 1.05, lower leverage |
| Dividends | Tie | Neither pays a meaningful dividend |
| Momentum (1Y) | SNDX | +38.8% vs EXEL's +13.9% |
| Efficiency (ROA) | EXEL | 24.0% ROA vs SNDX's -56.5%, ROIC 32.1% vs -68.8% |
Who Each Stock Is For
Income & stability
Growth exposure
Long-term compounding (10Y)
Sleep-well-at-night portfolio
Defensive / Recession hedge
Business Model
What each company does and how it makes money
Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company developing targeted cancer therapies. It generates revenue primarily through research collaborations and licensing agreements — with future potential from drug commercialization if its lead candidates gain approval. The company's competitive advantage lies in its specialized pipeline targeting specific cancer pathways like Menin inhibition and CSF-1 receptor blockade.
Exelixis is an oncology-focused biotechnology company that discovers, develops, and commercializes targeted cancer therapies. It generates revenue primarily from sales of its flagship drug Cabometyx — which accounts for the vast majority of its revenue — along with royalties from partnered products like Cotellic. The company's competitive advantage lies in its deep expertise in tyrosine kinase inhibitors and its focused pipeline targeting difficult-to-treat cancers.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
EXEL leads in 4 of 6 categories — strongest in Financial Metrics and Valuation Metrics. 1 category is tied.
Financial Metrics (TTM)
EXEL is the larger business by revenue, generating $2.3B annually — 20.5x SNDX's $112M. EXEL is the more profitable business, keeping 29.6% of every revenue dollar as net income compared to SNDX's -2.8%. On growth, SNDX holds the edge at +2.7% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | SNDXSyndax Pharmaceut… | EXELExelixis, Inc. |
|---|---|---|
| RevenueTrailing 12 months | $112M | $2.3B |
| EBITDAEarnings before interest/tax | -$285M | $830M |
| Net IncomeAfter-tax profit | -$312M | $678M |
| Free Cash FlowCash after capex | -$311M | $753M |
| Gross MarginGross profit ÷ Revenue | +92.3% | +96.6% |
| Operating MarginEBIT ÷ Revenue | -2.8% | +35.0% |
| Net MarginNet income ÷ Revenue | -2.8% | +29.6% |
| FCF MarginFCF ÷ Revenue | -2.8% | +32.9% |
| Rev. Growth (YoY)Latest quarter vs prior year | +2.7% | +10.8% |
| EPS Growth (YoY)Latest quarter vs prior year | +28.6% | +75.0% |
Valuation Metrics
| Metric | SNDXSyndax Pharmaceut… | EXELExelixis, Inc. |
|---|---|---|
| Market CapShares × price | $1.9B | $11.8B |
| Enterprise ValueMkt cap + debt − cash | $2.1B | $11.5B |
| Trailing P/EPrice ÷ TTM EPS | -5.82x | 15.85x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 13.29x |
| PEG RatioP/E ÷ EPS growth rate | — | 0.31x |
| EV / EBITDAEnterprise value multiple | — | 13.19x |
| Price / SalesMarket cap ÷ Revenue | 79.68x | 5.09x |
| Price / BookPrice ÷ Book value/share | 6.45x | 5.75x |
| Price / FCFMarket cap ÷ FCF | — | 13.36x |
Profitability & Efficiency
EXEL delivers a 31.4% return on equity — every $100 of shareholder capital generates $31 in annual profit, vs $-3 for SNDX. EXEL carries lower financial leverage with a 0.08x debt-to-equity ratio, signaling a more conservative balance sheet compared to SNDX's 1.20x. On the Piotroski fundamental quality scale (0–9), EXEL scores 7/9 vs SNDX's 3/9, reflecting strong financial health.
| Metric | SNDXSyndax Pharmaceut… | EXELExelixis, Inc. |
|---|---|---|
| ROE (TTM)Return on equity | -2.7% | +31.4% |
| ROA (TTM)Return on assets | -56.5% | +24.0% |
| ROICReturn on invested capital | -68.8% | +32.1% |
| ROCEReturn on capital employed | -57.8% | +35.0% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 7 |
| Debt / EquityFinancial leverage | 1.20x | 0.08x |
| Net DebtTotal debt minus cash | $192M | -$309M |
| Cash & Equiv.Liquid assets | $154M | $482M |
| Total DebtShort + long-term debt | $346M | $173M |
| Interest CoverageEBIT ÷ Interest expense | -12.81x | — |
Total Returns (with DRIP)
A $10,000 investment in EXEL five years ago would be worth $19,758 today (with dividends reinvested), compared to $8,990 for SNDX. Over the past 12 months, SNDX leads with a +38.8% total return vs EXEL's +13.9%. The 3-year compound annual growth rate (CAGR) favors EXEL at 37.1% vs SNDX's -5.0% — a key indicator of consistent wealth creation.
| Metric | SNDXSyndax Pharmaceut… | EXELExelixis, Inc. |
|---|---|---|
| YTD ReturnYear-to-date | +1.9% | +1.1% |
| 1-Year ReturnPast 12 months | +38.8% | +13.9% |
| 3-Year ReturnCumulative with dividends | -14.4% | +158.0% |
| 5-Year ReturnCumulative with dividends | -10.1% | +97.6% |
| 10-Year ReturnCumulative with dividends | +80.9% | +1110.4% |
| CAGR (3Y)Annualised 3-year return | -5.0% | +37.1% |
Risk & Volatility
EXEL is the less volatile stock with a 0.63 beta — it tends to amplify market swings less than SNDX's 1.05 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. SNDX currently trades 95.5% from its 52-week high vs EXEL's 88.8% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | SNDXSyndax Pharmaceut… | EXELExelixis, Inc. |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.05x | 0.63x |
| 52-Week HighHighest price in past year | $22.73 | $49.62 |
| 52-Week LowLowest price in past year | $8.58 | $32.38 |
| % of 52W HighCurrent price vs 52-week peak | +95.5% | +88.8% |
| RSI (14)Momentum oscillator 0–100 | 50.7 | 53.1 |
| Avg Volume (50D)Average daily shares traded | 1.0M | 2.1M |
Analyst Outlook
Wall Street rates SNDX as "Buy" and EXEL as "Buy". Consensus price targets imply 81.2% upside for SNDX (target: $39) vs 0.8% for EXEL (target: $44).
| Metric | SNDXSyndax Pharmaceut… | EXELExelixis, Inc. |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $39.33 | $44.40 |
| # AnalystsCovering analysts | 22 | 32 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | 1 | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +8.0% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Mar 20 | Feb 26 | Change |
|---|---|---|---|
| Syndax Pharmaceutic… (SNDX) | 100 | 230.31 | +130.3% |
| Exelixis, Inc. (EXEL) | 100 | 228.44 | +128.4% |
Exelixis, Inc. (EXEL) returned +98% over 5 years vs Syndax Pharmaceutic… (SNDX)'s -10%. A $10,000 investment in EXEL 5 years ago would be worth $19,758 today (including dividends reinvested).
Chart 2Revenue Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Syndax Pharmaceutic… (SNDX) | $1M | $24M | +1841.0% |
| Exelixis, Inc. (EXEL) | $191M | $2.3B | +1111.8% |
Exelixis, Inc.'s revenue grew from $191M (2016) to $2.3B (2025) — a 31.9% CAGR.
Chart 3Net Margin Trend — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Syndax Pharmaceutic… (SNDX) | -36.5% | -13.5% | +63.1% |
| Exelixis, Inc. (EXEL) | -36.7% | 33.7% | +192.0% |
Exelixis, Inc.'s net margin went from -37% (2016) to 34% (2025).
Chart 4P/E Ratio History — 9 Years
| Stock | 2017 | 2025 | Change |
|---|---|---|---|
| Exelixis, Inc. (EXEL) | 62 | 15.8 | -74.5% |
Exelixis, Inc. has traded in a 9x–62x P/E range over 9 years; current trailing P/E is ~16x.
Chart 5EPS Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Syndax Pharmaceutic… (SNDX) | -3.04 | -3.73 | -22.7% |
| Exelixis, Inc. (EXEL) | -0.28 | 2.78 | +1092.9% |
Exelixis, Inc.'s EPS grew from $-0.28 (2016) to $2.78 (2025).
Chart 6Free Cash Flow — 5 Years
Syndax Pharmaceuticals, Inc. generated $-275M FCF in 2024 (-1048% vs 2021). Exelixis, Inc. generated $884M FCF in 2025 (+163% vs 2021).
SNDX vs EXEL: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is SNDX or EXEL a better buy right now?
Exelixis, Inc. (EXEL) offers the better valuation at 15.8x trailing P/E (13.3x forward), making it the more compelling value choice. Analysts rate Syndax Pharmaceuticals, Inc. (SNDX) a "Buy" — based on 22 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — SNDX or EXEL?
Over the past 5 years, Exelixis, Inc. (EXEL) delivered a total return of +97.6%, compared to -10.1% for Syndax Pharmaceuticals, Inc. (SNDX). A $10,000 investment in EXEL five years ago would be worth approximately $20K today (assuming dividends reinvested). Over 10 years, the gap is even starker: EXEL returned +1110% versus SNDX's +80.9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — SNDX or EXEL?
By beta (market sensitivity over 5 years), Exelixis, Inc. (EXEL) is the lower-risk stock at 0.63β versus Syndax Pharmaceuticals, Inc.'s 1.05β — meaning SNDX is approximately 67% more volatile than EXEL relative to the S&P 500. On balance sheet safety, Exelixis, Inc. (EXEL) carries a lower debt/equity ratio of 8% versus 120% for Syndax Pharmaceuticals, Inc. — giving it more financial flexibility in a downturn.
04Which has better profit margins — SNDX or EXEL?
Exelixis, Inc. (EXEL) is the more profitable company, earning 33.7% net margin versus -1346.1% for Syndax Pharmaceuticals, Inc. — meaning it keeps 33.7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: EXEL leads at 37.6% versus -1434.4% for SNDX. At the gross margin level — before operating expenses — EXEL leads at 96.6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Is SNDX or EXEL more undervalued right now?
Analyst consensus price targets imply the most upside for SNDX: 81.2% to $39.33.
06Which pays a better dividend — SNDX or EXEL?
None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is SNDX or EXEL better for a retirement portfolio?
For long-horizon retirement investors, Exelixis, Inc. (EXEL) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.63), +1110% 10Y return). Both have compounded well over 10 years (EXEL: +1110%, SNDX: +80.9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between SNDX and EXEL?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. In terms of investment character: SNDX is a small-cap quality compounder stock; EXEL is a mid-cap deep-value stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.